Answers are grounded in this paper and cite their sources.
Atezolizumab plus PEGPH20 showed limited clinical activity in patients with PDAC and none in patients with GC. The safety of atezolizumab plus PEGPH20 was consistent with each agent's known safety profile. (ClinicalTrials.gov Identifier: NCT03193190 and NCT03281369).
No takes yet. Share an insight, caveat, or question.
Ko et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: